Your browser doesn't support javascript.
loading
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos, Theodoros; Pergolini, Ilaria; Castillo, Carlos Fernández-Del; Honselmann, Kim C; Cai, Lei; Deshpande, Vikram; Wo, Jennifer Y; Ryan, David P; Allen, Jill N; Blaszkowsky, Lawrence S; Clark, Jeffrey W; Murphy, Janet E; Nipp, Ryan D; Parikh, Aparna; Qadan, Motaz; Warshaw, Andrew L; Hong, Theodore S; Lillemoe, Keith D; Ferrone, Cristina R.
Afiliação
  • Michelakos T; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Pergolini I; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Castillo CF; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Honselmann KC; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Cai L; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Deshpande V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Wo JY; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Ryan DP; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Allen JN; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Blaszkowsky LS; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Clark JW; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Murphy JE; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Nipp RD; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Parikh A; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Qadan M; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Warshaw AL; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Lillemoe KD; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Ferrone CR; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Ann Surg ; 269(4): 733-740, 2019 04.
Article em En | MEDLINE | ID: mdl-29227344
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Surg Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Marrocos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Surg Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Marrocos